Nephrotoxic Nephritis (NTN) : Possible new therapeutic strategy using DHMEQ, a nuclear uptake inhibitor of NF-kappa B

Abstract

Inflammatory glomerular kidney diseases (glomerulonephritis) are causing, in spite of some progress in the therapy, still in about 20-30% of the cases end stage renal disease. Understanding the pathogenesis of inflammatory diseases persistently improved further in the past years through following reasons among others:

By describing the role of transcription factors, that all ahead of NF kappa B, with that induction of inflammatory diseases occurs and By showing, that NF kappa B has also a decisive importance in the resolution phase of inflammation processes.

The team was able to publish recently that it comes after induction of experimental kidney diseases into a two phase activation of NF kappa B. In the first peak, the p65/p50 heterodimer protein complex dominates, in the second peak the p50/p50 homodimers. Goal of the graduation work therefore is to examine the effect of the inhibition of the nuclear reception of NF kappa B complexes by means of in vivo application of DHMEQ at different times after induction of the NTN in wild type mice.